Front. Aging Frontiers in Aging Front. Aging 2673-6217 Frontiers Media S.A. 804856 10.3389/fragi.2021.804856 Aging Correction Corrigendum: In Vivo Pooled Screening: A Scalable Tool to Study the Complexity of Aging and Age-Related Disease Borch Jensen and Marblestone Corrigendum: In Vivo Pooled Screening Borch Jensen Martin 1 * Marblestone Adam 2 3 * Gordian Biotechnology, San Francisco, CA, United States Astera Institute, San Francisco, CA, United States Federation of American Scientists, Washington D.C., CA, United States

Edited and reviewed by: Christian G. Riedel, Karolinska Institutet (KI), Sweden

 *Correspondence: Martin Borch Jensen, martin@gordian.bio; Adam Marblestone, adam@astera.org

This article was submitted to Interventions in Aging, a section of the journal Frontiers in Aging

 03 12 2021 2021 2 804856 29 10 2021 17 11 2021 Copyright © 2021 Borch Jensen and Marblestone. 2021 Borch Jensen and Marblestone

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on In Vivo Pooled Screening: A Scalable Tool to Study the Complexity of Aging and Age-Related Disease by Borch Jensen, M., and Marblestone, A. (2021). Front. Aging 2:714926. doi:10.3389/fragi.2021.714926 in vivo pooled screening direct in vivo screening aging models animal models gene therapy single cell sequencing barcoding

In the original article, there was a mistake in Table 1 as published. A typo caused the entry for “Optimal payload size” for AAV to be listed as 3–4.5 kb, rather than the intended 4–4.5 kb. The corrected Table 1 appears below.

Delivery modalities for in vivo pooled screening

AAV Lentivirus Adenovirus Lipid nanoparticle (with mRNA/siRNA) siRNA/antisense oligos
Targetable tissues and cell types Many (liver, muscle, brain, eye, lung, heart, and more) Many Many Mainly hepatocytes, vasculature reported Mainly liver and kidney, neurons with direct injection
Inter- and intra-tissue spread Medium-high Low Low Medium High
Duration of treatment possible Stable episomal expression in non-dividing cells for months+ Stable integration in dividing and non-dividing Stable episomal expression in non-dividing cells for months+ Days to weeks, unless gene editing modalities delivered Days to weeks
Optimal payload size 4–4.5 kb 7–8 kb 8–30 kb Any <100 bp
Payload vector construction Moderate Moderate Hard Easy Easy but expensive
Immunogenicity Low Medium High Low Low-High

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.